NCT06529588

Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients

Soluble Urokinase Plasminogen Activator Receptor (suPAR) is a Potential Biomarker of Stage III-IV, Grade C Periodontitis Through the Impact of Post-radiotherapy on Head and Neck Cancer Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 150 (actual)
• Sponsor: Al-Maarif University College · Academic / Other
• Sex: All
• Age: 28 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).

Detailed description

The urokinase-type plasminogen activator receptor (uPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of chronic periodontitis. The study enrolled 150 participants, 50 chronic periodontitis with head and neck cancer post radiotherapy (CP+HNC post-RT) patients, 50 chronic periodontitis (CP) without HNC patients, and 50 healthy controls. Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Plaque Index (PI), and Gingival Bleeding Index (GBI) were recorded. An enzyme-linked immunosorbent assay (ELISA) was constructed to quantify serum (suPAR) levels.

Conditions

• Head and Neck Cancer
• Chronic Periodontitis
• Radiotherapy Side Effect

Interventions

Type	Name	Description
RADIATION	Radiation	HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months

Timeline

• Start date: 2022-09-01
• Primary completion: 2023-01-09
• Completion: 2023-10-23
• First posted: 2024-07-31
• Last updated: 2024-07-31

Locations

1 site across 1 country: Iraq